BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Autoimmunity
,
Ciprofibrate
,
rs3825942
,
EGFR
,
cell-cell adhesion
,
Allergy to pollen
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
carcinomas parathyroid
Summary
General Info
Curated Studies
Most Correlated Studies
OMIM - Malignant neoplasms
Cancer Gene Census - mutations in cancer genes
OMIM - Neoplasms
L1000 CMAP - Carcinoma of prostate PC3 cells treated with ligand perturbagens
L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
Parathyroid carcinoma: molecular therapeutic targets.
Update on the medical management of parathyroid carcinoma].
Approach to the Patient With Parathyroid Carcinoma.
Parathyroid carcinoma: Three case reports.
Single-Cell Transcriptomic Atlas of Parathyroid Adenoma and Parathyroid Carcinoma.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
European Multicentric Study on Parathyroid Carcinoma
Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma o…
An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With P…
Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristic…
Differentially Expressed Proteins in Sporadic Parathyroid Tumors
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ